Managing plasmids from design to distribution.

Vision

GenoFAB's biofoundry services integrate engineering and data science to develop plasmids that meet your project's unique requirements.

 

genofab-text-about
Illustration of data-line lines spread from left and right, coming together in the center with a ring symbolizing GenoFAB

GenoFAB's 'data first' philosophy is more than a belief. It's a strategic approach that underlines the importance of data as a foundational element in the decision-making, development, and operations of R&D projects. This core principle is designed to maximize shareholder value by supporting strong patent claims while ensuring freedom to operate.

Biofoundry-enabled R&D

The Power of Performance. Unified. Configured. Optimized.

Our biofoundry is the critical infrastructure that supports our plasmid management services. It combines data science and automation to enable rapid plasmid prototyping. GenoFAB Biofoundry Operating System enhances collaboration and accelerates the design, production, and preclinical testing of new plasmids.

Nobody else does it the GenoFAB way. A faster, more streamlined research and development process bolsters your Return on Investment in R&D by intensely reducing time to market and securing a defendable intellectual property position. 
software icon-Sep-19-2023-06-10-15-0389-PM

Software

Proprietary lab operating system
equipment-1

Equipment

Specialized tools for lab work
processes-1

Processes

Defined rules for lab operations
personnel

Personnel

Skilled talent managing R&D
Illustration of thousands of data-line lines spaced wide at the top and coming together at the bottom, symbolizing refinement to a point
We bring the next generation of plasmids and expression systems to your project so you can make breakthrough discoveries, develop life-saving drugs, and build a sustainable economy .

An Industry in Dire Need of Change

Combining automation and data science is key to improving the reproducibility and productivity of life science research and development.
1.2%

Return from pharma innovation 

Deloitte has been publishing an annual report estimating the return on investment in pharmaceutical research and development. These reports show a long-term decline in productivity that reached 1.2% in 2022 before bouncing back to 4.1% in 2023. If this trend continues, the ROI will become negative around 2030. 

Deloitte: Unleash AI’s potential Measuring the return from pharmaceutical innovation – 14th edition
>50%

Error rate in lab-made plasmids 

The analysis of more than 2,500 plasmids provided by the clients of a contract research organization shows that more than half them have major problems. Some are poorly designed making them unlikely to achieve the intended function. Others do not match their published sequences. 

Nature: Serious errors plague DNA tool that’s a workhorse of biology.
$28,000,000,000

Annual U.S. Spending on Non-Reproducible
Preclinical Research

Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, resulting in approximately US $28,000,000,000 (US$28B) per year spent on preclinical research that is not reproducible — in the United States alone.

PLOS: The Economics of Reproducibility in Preclinical Research
70%+ Failure

Attempts to reproduce published results

More than 70% of researchers have tried and failed to reproduce another scientist's experiments, and more than half have failed to reproduce their own experiments. 

Nature: More Than 1,500 Scientist Lift The Lid On Reproducibility

Why GenoFAB? Why Now?

Simply because the biotechnology industry and life science community are facing an existential productivity crisis. 

We need to challenge the status quo to accelerate the development of biological products  that save lives, feed the world, and build a sustainable future. 

We make it faster.

Because if you’re not first,

you’re last.

When it comes to intellectual property, time is of the essence. There is no consolation prize for being the second to file a patent application. By partnering with GenoFAB to design, build, and manage your plasmids, you will accelerate the production of reproducible data that will support stronger patent applications.

You need speed.

You need robust evidence.

Our technologies deliver just that.

It takes a village to save a life

GenoFAB was founded to mitigate the technical and human risks of developing biotechnology products. We know how to manage plasmids. It's our expertise. 

Your expertise allows you to design and test these plasmids.  

You need an engineering partner.

We need an application partner.

Together, we can make a difference. 
 

Let’s give your team the plasmids they are waiting for!

Pick a time to learn more about our plasmid management services. 

Schedule a call
genofab-symbol-purple-1 linkedin

Terms   Privacy Policy   Disclaimers
© 2023 GenoFAB, Inc. All rights reserved.